Additional file 1: of Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells

Table S1. Consistently differentially expressed miRNAs

Additional file 2: of Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells

Table S2. Consistently differentially expressed mRNAs

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

<div><p>Purpose</p><p>Cellular immunotherapy has appeared to be a promising modality for the treatment of malignant tumor. The objective of this study was to evaluate the efficacy of cellular immunotherapy combined with minimally invasive therapy.</p><p>Methods</p><p>We searched PubMed, Web of Science and The Cochrane Library through March 2016 for relevant studies. Short-term efficacy (the disease control rate, the control rate of quality life and the AFP descent rate) and long-term efficacy (overall survival (OS) and progression-free survival (PFS) rate) were compared as the major outcome measures. The meta-analysis was performed using Review Manager 5.3.</p><p>Results</p><p>A total of 1174 references in 3 databases were found of which 19 individual studies with 1774 HCC patients enrolled in this meta-analysis. Meta-analysis results showed that cellular immunotherapy combined with minimally-invasive treatment significantly improved the measures of short-term response (the disease control rate (OR = 5.91, P = 0.007), the control rate of quality lift (OR = 3.38, P = 0.003) and the AFP descent rate (OR = 4.48, P = 0.02)). Also higher 6-month PFS (OR = 2.78, P = 0.05), ≥12-month PFS (OR = 3.56, P<0.00001) rate and 6-month OS (OR = 2.81, P = 0.0009), 12-month OS (OR = 3.05, P<0.00001) and 24-month OS (OR = 3.52, P<0.0001) rate were observed in patients undergoing cellular immunotherapy.</p><p>Conclusions</p><p>This meta-analysis suggested that cellular immunotherapy is a feasible adjuvant treatment that could be beneficial for the improvement of the clinical outcomes for hepatocellular carcinoma (HCC) patients after minimally invasive treatment, including short-term response and long-term survival.</p></div

Establishment of Mouse Teratocarcinomas Stem Cells Line and Screening Genes Responsible for Malignancy

<div><p>The sequential transplantation of embryonal carcinoma cells <em>in vivo</em> can accelerate the growth and malignancy of teratocarcinomas. However, the possible molecular mechanisms in this process that reflect cancer formation in the early stage are largely unknown and. To identify which genes are associated with the changes of malignancy of teratocarcinomas, we established a tumorigenesis model in which teratocarcinoma were induced via injecting embryonic stem cells into immuno-deficiency mice, isolating teratocarcinoma stem cell from a teratocarcinoma in serum-free culture medium and injecting teratocarcinoma stem cells into immune-deficient mice continuously. By using high-throughput deep sequence technology, we identified 26 differentially expressed genes related to the changes of characteristics of teratocarcinoma stem cell in which 18 out of 26 genes were down-regulated and 8 genes were up-regulated. Among these genes, several tumor-related genes such as <em>Gata3</em>, <em>Arnt</em> and <em>Tdgf1</em>, epigenetic associated genes such as <em>PHC1</em> and <em>Uty</em> were identified. Pathway enrichment analysis result revealed that Wnt signaling pathway, primary immunodeficiency pathway, antigen processing and presentation pathway and allograft rejection pathway were involved in the teratocarcinoma tumorigenesis (corrected <em>p</em> value<0.05). In summary, our study established a tumorigenesis model and proposed some candidate genes and signaling pathways that may play a key role in the early stage of cancer occurrence.</p> </div

MOESM1 of The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors

Additional file 1: Figure S1. Changes of serum level of AFP and CEA pre- and post-treatment in five types of tumors. Analysis of the changes of AFP and CEA in patients with cholangiocarcinoma, colon cancer, primary liver cancer, gastric cancer and lung cancer pre-therapy and post-treatment, respectively. *Statistically significant differences (*p < 0.05)

The malignant degree of teratocarcinoma increased after sequential transplantation.

<p>A. Different generation of teratocarcinoma stem cells and ES cells were injected subcutaneously into nude mice on both sides of the body; the teratocarcinoma growth of G3 cells was significantly faster than that of ES cells. B. With the increasing of transplantation generation, it accelerated the tumor formation of teratocarcinoma stem cells.</p

Bioinformatics analysis of mouse teratocarcinoma microarray dataset.

<p>A. Scatter plots of global gene expression patterns between teratocarcinoma sample(y axis) and ES sample (x axis). Red, gray and blue represent gene expression levels up, equivalent and down between the samples. The positions of pluripotent genes such as Oct4, Sox2, Nanog were marked by green spot. B. Two-way hierarchical global clustering of microarray dataset C. Overlapping analysis of two groups of genes. D. Two-way hierarchical clustering of 26 identified genes. E. the result of chromosome enrichment analysis of 26 interested genes.</p

Changes of characteristics of teratocarcinoma stem cells after sequential transplantation.

<p>A. the growth curve of teratocarcinoma stem cell marked doubling time. B Decreasing or disappearing expression of pluripotency-related genes of G3 cell cultured by DMEM +10% FBS.</p

Comparison of short-term efficacy between the patients undergoing cellular immunotherapy or not by using the random effects model (Mantel-Haenszel method).

<p>Comparison of short-term efficacy between the patients undergoing cellular immunotherapy or not by using the random effects model (Mantel-Haenszel method).</p

The feature of teratocarcinoma stem cells.

<p>A. the phenotype of clones was same as that of ES cells. B. the clones formed by 6-day-cultured single cell. C: expressing pluripotency-related genes including Oct4, Sox2 and Nanog with alkaline phosphatase-positive.</p